Medicus Pharma Ltd $MDCX Stock: Interchange Capital Partners LLC Raises Stake

Interchange Capital Partners LLC raised its holdings in Medicus Pharma Ltd (NASDAQ:MDCX) by 33.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,124,910 shares of the company’s stock after buying an additional 538,039 shares during the quarter. Interchange Capital Partners LLC’s holdings in Medicus Pharma were worth $343,000 as of its most recent SEC filing.

Separately, Sterling Investment Advisors Ltd. acquired a new stake in shares of Medicus Pharma during the 2nd quarter worth approximately $45,000.

Analyst Upgrades and Downgrades

MDCX has been the subject of several research analyst reports. Alliance Global Partners reiterated a “buy” rating on shares of Medicus Pharma in a research note on Monday, September 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a research note on Friday, October 2nd. Finally, Wall Street Zen lowered shares of Medicus Pharma to a “strong sell” rating in a research note on Saturday, October 17th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $450.00.

Medicus Pharma Price Performance

Shares of MDCX opened at $1.88 on Friday. The stock has a 50-day moving average of $7.27 and a 200-day moving average of $23.43. The company has a market cap of $2.37 million, a PE ratio of -0.02 and a beta of 0.30. Medicus Pharma Ltd has a one year low of $1.82 and a one year high of $127.50.

Medicus Pharma (NASDAQ:MDCX) last issued its earnings results on Wednesday, August 12th. The company reported ($10.50) EPS for the quarter, missing analysts’ consensus estimates of ($6.38) by ($4.12). Analysts expect that Medicus Pharma Ltd will post -36.25 EPS for the current fiscal year.

Medicus Pharma Profile

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.

Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.